ArticleCytotherapy2012
Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition.
Article in Cytotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Harnessing Lessons from Gel-Based and Advanced Biomaterial Therapeutics to Enable Direct Cellular Reprogramming.Gels (Basel, Switzerland) · 2026Review
- Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments.Biomedicines · 2023Review
- Review
- Echocardiography-guided percutaneous left ventricular intracavitary injection as a cell delivery approach in infarcted mice.Molecular and cellular biochemistry · 2021Article
- High concentrations of H7 human embryonic stem cells at the point of care for acute myocardial infarction.Annals of translational medicine · 2020Article
- Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction.Stem cell reports · 2018Article
- Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration.Stem cells international · 2018Review
- From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications.International journal of stem cells · 2017Review
- Adipose tissue-derived stem cells suppress hypertrophic scar fibrosis via the p38/MAPK signaling pathway.Stem cell research & therapy · 2016Article
- New Trends in Heart Regeneration: A Review.Journal of stem cells & regenerative medicine · 2016Review
- Cardiac stem cell therapy: Have we put too much hype in which cell type to use?Heart failure reviews · 2015Review
- HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth.Cell reports · 2015Article
- Treatment with hESC-Derived Myocardial Precursors Improves Cardiac Function after a Myocardial Infarction.PloS one · 2015Article
- Small molecules for cell reprogramming and heart repair: progress and perspective.ACS chemical biology · 2014Review
- The effects of aging on apoptosis following myocardial infarction.Cardiovascular therapeutics · 2013Article
- Improving survival and efficacy of pluripotent stem cell-derived cardiac grafts.Journal of cellular and molecular medicine · 2013Review
- Marching towards regenerative cardiac therapy with human pluripotent stem cells.Discovery medicine · 2013Review
- Article
- Embryonic stem cells for severe heart failure: why and how?Journal of cardiovascular translational research · 2012Review
- Strategies for enrichment and selection of stem cell-derived tissue precursors.Stem cell research & therapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND
aimsWe have shown previously that inhibition of the p38 mitogen-activated protein kinase (p38MAPK) directs the differentiation of human embryonic stem cell (hESC)-derived cardiomyocytes (hCM). We investigated the therapeutic benefits of intramyocardial injection of hCM differentiated from hESC by p38MAPK inhibition using closed-chest ultrasound-guided injection at a clinically relevant time post-myocardial infarction (MI) in a mouse model.
methodsMI was induced in mice and the animals treated at day 3 with: (a) hCM, (b) human fetal fibroblasts (hFF) as cell control, or (c) medium control (n = 10 animals/group). Left ventricular ejection fraction (LVEF) was evaluated post-MI prior to therapy, and at days 28 and 60 post-cell therapy. Hearts were analyzed at day 60 for infarct size, angiogenesis, cell fate and teratoma formation.
resultsLVEF was improved in the hCM-treated animals compared with both hFF and medium control-treated animals at day 28 (39.03 ± 1.79% versus 27.89 ± 1.27%, P < 0.05, versus 32.90 ± 1.46%, P < 0.05, respectively), with sustained benefit until day 60. hCM therapy resulted in significantly smaller scar size, increased capillary bed area, increased number of arterioles, less native cardiomyocyte (CM) apoptosis, and increased CM proliferation compared with the other two groups. These benefits were achieved despite a very low retention rate of the injected cells at day 60, as assessed by immunohistochemistry and quantitative real-time polymerase chain reaction (qPCR). Therapy with hCM did not result in intramyocardial teratoma formation at day 60.
conclusionsThis study demonstrates that hCM derived from p38MAPK-treated hESC have encouraging therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.